Educational reference only. Not medical advice. Research compounds are not for human or veterinary use.

HGH for anti-aging: what the research really shows

Human growth hormone (hGH) is sold online and in "longevity" clinics as a way to turn back the clock. The logic sounds simple: growth hormone falls with age, so putting it back should make us younger. The research is less flattering. In healthy older adults, growth hormone shifts body composition a little, does not make people stronger and causes more side effects. In the United States, distributing it for anti-aging is also a federal crime. Here is what the studies show and what is still unknown.

What growth hormone and IGF-1 do

  • Growth hormone is a protein hormone made by the pituitary gland at the base of the brain. It drives growth in childhood and helps maintain tissues and organs throughout life.
  • IGF-1 (insulin-like growth factor 1) carries out many of growth hormone's effects. Most of the IGF-1 in the blood is made in the liver in response to growth hormone.
  • Together they help maintain muscle and bone and promote the breakdown of fat.

How levels change with age

Growth hormone output peaks at puberty and then falls. A review in the clinical reference Endotext describes a decline of roughly 15% per decade of adult life, driven mainly by smaller hormone pulses. IGF-1 falls with it. The same review states that aging by itself is not a reason to test for or treat growth hormone deficiency.

What growth hormone is approved for

Growth hormone is a prescription drug. The FDA has approved it for a limited set of conditions. According to the FDA and the DEA, these include:

  • In children: growth failure linked to growth hormone deficiency, chronic kidney disease, Turner syndrome, Prader-Willi syndrome, Noonan syndrome, SHOX deficiency, small for gestational age, and idiopathic short stature.
  • In adults: growth hormone deficiency (starting in childhood or adulthood), short bowel syndrome in people receiving specialized nutritional support, and the wasting syndrome of HIV/AIDS.

Newer once-weekly options exist too; in July 2025 the FDA approved lonapegsomatropin (Skytrofa) for adult growth hormone deficiency. Aging, low energy and "optimization" are not on the list.

What the law says

U.S. federal law treats growth hormone differently from most prescription drugs. Under 21 U.S.C. 333(e), knowingly distributing human growth hormone, or possessing it with intent to distribute, for any use in humans other than the treatment of a disease or other recognized medical condition that HHS has authorized and a physician has ordered is a crime punishable by up to 5 years in prison. If the offense involves a person under 18, the maximum rises to 10 years. The law defines human growth hormone as somatrem, somatropin or an analogue of either.

  • Anti-aging is not an authorized use. The FDA's import alert on growth hormone, updated in April 2026, says HHS has not authorized anti-aging use and notes that longevity clinics sell it as a "fountain of youth."
  • Compounding is not a workaround. The same alert says growth hormone is not eligible for the 503A compounding exemptions, and that a product containing it cannot be a dietary supplement.

The anti-aging evidence

Rudman 1990: the study that started it

In 1990, the New England Journal of Medicine published a study of 21 healthy men aged 61 to 81 with low IGF-1. Twelve received growth hormone for six months; nine served as untreated controls. In the treated men, lean body mass rose 8.8%, fat mass fell 14.4% and lumbar spine bone density rose 1.6%. Skin thickness rose 7.1%, but that change was not statistically significant.

The study was small and short. It measured body composition, not strength, function or lifespan, and the comparison group got no placebo.

Blackman 2002: a larger controlled trial

A randomized trial published in JAMA in 2002 assigned 57 men and 74 women aged 65 to 88 to growth hormone, sex hormones, both, or placebo for 26 weeks. Growth hormone increased lean mass and reduced fat in both sexes. There was no clear effect on muscle strength. Only men given growth hormone plus testosterone improved on a treadmill test of endurance. (For more on testosterone itself, see our post on TRT benefits and hormonal optimization.)

Side effects affected up to 40% of volunteers, mostly in the growth hormone groups, and included swelling, joint pain and carpal tunnel syndrome. Eighteen men on growth hormone developed glucose intolerance or diabetes, versus seven men not on it. These resolved within weeks of stopping. The lead author said the treatment was "not ready for prime time."

Liu 2007: the systematic review

A 2007 systematic review in Annals of Internal Medicine pooled 31 articles describing 18 study groups of healthy older adults (average age 69). In total, 220 people received growth hormone, for an average of about 27 weeks. Compared with no treatment:

  • Body composition: fat mass fell by about 2.1 kg and lean mass rose by about 2.1 kg. Body weight did not change.
  • Other outcomes: bone density and most blood lipids did not change.
  • Side effects: people on growth hormone were significantly more likely to have soft-tissue swelling, joint pain, carpal tunnel syndrome and breast enlargement in men, and somewhat more likely to develop diabetes or impaired fasting glucose.

Most studies were small, and the authors concluded that growth hormone cannot be recommended as an anti-aging therapy. Mayo Clinic puts it simply: the gain in muscle "doesn't lead to gains in strength."

Side effects

Across these trials and expert summaries, the side effects in healthy adults are consistent:

  • Swelling and pain: fluid retention in the limbs, and joint and muscle pain.
  • Carpal tunnel syndrome: a pinched nerve in the wrist causing numbness and tingling.
  • Breast enlargement in men (gynecomastia).
  • Blood sugar problems: high blood sugar, reduced insulin sensitivity and type 2 diabetes.

Long-term effects are poorly understood, because the trials were small and short.

Cancer and IGF-1

Growth hormone and IGF-1 promote cell growth, which raises a fair question about cancer.

  • Population data: a large UK Biobank analysis of about 397,000 people, combined with a genetic (Mendelian randomization) analysis, found that higher circulating IGF-1 was associated with a higher risk of colorectal cancer, and the authors suggested the link may be causal.
  • Treatment data: in adults with genuine growth hormone deficiency, the Endotext review says there is no definitive evidence that replacement increases the risk of new or recurring cancer. Growth hormone is not given to people with active cancer, and the DEA notes it may increase the growth of existing malignant cells.
  • What is missing: no trial in healthy older adults has run long enough to measure cancer outcomes.

The longevity paradox

Here is the twist: in animals and some people, lower, not higher, growth hormone signaling is linked to healthier aging.

  • In mice: the Endotext review reports that mice with growth hormone resistance and very low IGF-1 appear healthy and live longer, that mice with a mutation blocking pituitary growth hormone production live about 42% longer, and that treating mice with growth hormone shortens lifespan.
  • In people with Laron syndrome: this rare condition, caused by a faulty growth hormone receptor, leaves people very short. In a group of about 99 people in Ecuador followed for roughly 22 years, researchers found one non-fatal cancer, compared with cancer in 17% of unaffected relatives, and no diabetes, compared with 5% of relatives.
  • But not longer lives: people with Laron syndrome in that study did not appear to live longer. They had high rates of death from accidents and alcohol. The Endotext review adds that no formal longevity studies have been done in humans with dwarfism.

None of this proves that lowering growth hormone extends human life, but it undercuts the idea that raising it is a path to longevity.

Growth hormone secretagogues

Secretagogues prompt the pituitary to release more of the body's own growth hormone and are often marketed as a gentler alternative:

  • Sermorelin: an analogue of growth hormone releasing hormone (GHRH). It was once FDA-approved as Geref; the maker discontinued it in 2008, and the FDA later found this was not for safety or effectiveness reasons. In one six-month GHRH trial in older adults, body composition improved but strength and aerobic fitness did not. See our sermorelin brief.
  • Tesamorelin: a GHRH analogue approved by the FDA in 2010 (Egrifta) only to reduce excess abdominal fat in people with HIV-associated lipodystrophy. More people on it had worsening blood sugar in its trials. See our tesamorelin brief.
  • Ipamorelin: a synthetic growth hormone secretagogue. Not FDA-approved. The FDA lists it among compounding substances that may present significant safety risks, citing possible immune reactions and serious adverse events, including death, in an intravenous study. See our ipamorelin brief.
  • CJC-1295: a GHRH analogue that is not FDA-approved. The FDA has said clinical data are limited and that it identified serious adverse events, including increased heart rate. It is often sold paired with ipamorelin; see our CJC-1295 + ipamorelin brief.
  • MK-677 (ibutamoren): an oral ghrelin mimetic, not approved for any use. In a randomized trial of 65 healthy adults aged 60 to 81, it raised fat-free mass by 1.1 kg at one year (versus a 0.5 kg loss on placebo) but did not change strength or function. Fasting blood sugar rose and insulin sensitivity fell. The FDA also notes that a separate trial was stopped early over a possible signal of congestive heart failure. See our MK-677 brief.

The pattern mirrors growth hormone: body composition moves, functional benefits are inconsistent and long-term outcomes are unstudied. None of these secretagogues were among the peptides reviewed at the FDA's July 2026 advisory meeting or covered by the HHS 503A peptide policy announced on October 28, 2026.

Counterfeit and unregulated growth hormone

Much of what is sold for anti-aging comes from outside the regulated supply. The DEA lists counterfeit, stolen and smuggled hGH, internet pharmacies and anti-aging clinics among illicit sources. The FDA's import alert covers unapproved growth hormone, mostly from firms in China, including products labeled as something else that contained undeclared growth hormone. In 2025, U.S. Customs and Border Protection reported seizing dozens of shipments of counterfeit growth hormone and steroids in Chicago. With these products, you cannot know what is in the vial. Read more on grey-market products versus compounding pharmacies.

Sport

The World Anti-Doping Agency bans growth hormone, its analogues and fragments at all times, along with GHRH analogues such as sermorelin, tesamorelin and CJC-1295 and secretagogues such as ipamorelin and MK-677.

The bottom line

For people with a diagnosed deficiency or another approved condition, growth hormone is a legitimate treatment. For healthy adults hoping to slow aging, the evidence is thin and mostly old: a small trade of fat for lean mass, no gain in strength or function and more side effects, including blood sugar problems. Long-term cancer and survival effects are unknown, and longevity research points, if anything, the other way. In the U.S., distributing growth hormone for anti-aging is illegal. If you are worried about your hormone levels, start with a licensed clinician who can test for a real deficiency.

Key references

This post is educational. It does not give dosing guidance and is not medical advice. Growth hormone is a prescription drug; decisions about it belong with a licensed clinician.

Educational content only

Peptide Knowledge is an educational reference. Nothing on this site is medical advice, a treatment recommendation or dosing guidance. Many compounds described here are not approved for human use and are sold for laboratory research only. Talk to a licensed clinician before starting, stopping or changing any medication or supplement.

All blog posts